Psoriasis drug study targets immune marker IL-33
NCT ID NCT07557095
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how two common psoriasis drugs, cyclosporine and methotrexate, affect a protein called IL-33 in the blood. Researchers will measure IL-33 levels and track psoriasis severity in 118 adults with moderate to severe psoriasis. The goal is to understand how these drugs work and which one may better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGYPTIAN PSORIATIC PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.